Viridian Therapeutics, Inc.

Viridian Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. Their expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases. The company is advancing multiple late-stage candidates for thyroid eye disease (TED) and a portfolio of neonatal Fc receptor (FcRn) inhibitors for autoimmune diseases.